Youth with epilepsy (YWE) are 2-3 times more likely than the average population to develop depression, controlling for other physical and behavioral health variables. 1 Depression or clinical depressive symptoms are present in 10-30% of YWE. [1] [2] [3] [4] Suicidal ideation (SI) is common in YWE, with at least one fourth of the population reporting SI. 1, 2, 4 Because of the overlap between antiepileptic drug (AED) side effects, seizure semiology, and depressive symptoms in youth (e.g., irritability, loss of energy, mood changes, and difficulties with attention and concentration), a differential diagnosis of depression in YWE can be challenging. 5 Furthermore, the U.S. Food and Drug Administration (FDA) has issued an alert for risk of increased SI with AED use in YWE, 6 complicating the clinical assessment of depressive symptoms in YWE. On the other hand, studies have shown that treatment of depression in individuals with epilepsy is associated with a reduction in reported adverse AED side effects. 7 Findings on the relationship between seizure variables (e.g., frequency, severity, and type) and sociodemographic (e.g., age, and gender) and depressive symptoms have been unequivocal, with some studies showing a relationship and others finding no association. 2, 3, 14 Experts have agreed that the relationship between epilepsy, SI, sociodemographic variables, and AED use is complex and multifactorial. 8 Depressive symptom screening measures have recently been developed specifically for YWE. The 11-item Neurological Disorders Depression Inventory-Epilepsy for Youth (NDDI-E-Y) was adapted from the adult version of the NDDI-E, which excluded symptoms related to AED side effects. [9] [10] [11] The NDDI-E-Y has shown promising psychometric properties. 10, 12 In addition, the Pediatric Neuro-QOL was designed to assess health-related quality of life (HRQoL) in children with neurologic conditions, including epilepsy, and contains an 8-item Depression Short Form (Neuro-QOL SF). 13, 14 Indeed, recent research supports specific clusters of depressive symptoms in persons with epilepsy, with the more common cluster consisting of a cognitive phenotype (e.g., self-critical cognitions, such as ineffectiveness), providing a rationale for examining specific clusters of depressive symptoms in youth with epilepsy. 29 The current gold standard self-report evaluation of pediatric depressive symptoms is the Children's Depression Inventory-2 (CDI-2), which has been used in both epilepsy clinical and research settings, 2, 12 and is listed as a common data element for depression in pediatric epilepsy (https://commondataelements.ninds.nih.gov/Epilepsy.aspx# tab=Data_Standards). Given the cost (approximately $2 per administration) and interpretation (requires training) of the CDI-2, it is not always feasible to use in routine epilepsy care. Therefore, the current study aimed to compare the performance of the NDDI-E-Y and the Neuro-QOL SF in the prediction of CDI-2 scores. Specifically, our aims were to determine whether (1) the NDDI-E-Y predicts overall depressive symptoms (CDI-2 Total score) or specific depressive symptom clusters (e.g., CDI-2 subscales) as single predictor in the model and when adjusted for covariates and (2) the NDDI-E-Y or Neuro-QOL SF is a better predictor of CDI-2 Total and subscale scores in youth with epilepsy. After controlling for demographic and seizure variables, we hypothesized that the NDDI-E-Y would explain more variance in the CDI-2 Ineffectiveness & Negative Self-Esteem subscales, given the content validity (domains of depression assessed) of and exclusion of AEDrelated symptoms on the NDDI-E-Y (aim 1). We also hypothesized that, after controlling for demographic and seizure variables, the NDDI-E-Y would be a better predictor compared to the Neuro-QOL SF of CDI-2 scores (aim 2).
Methods

Participants
Participants , and could read and write English. YWE who had a documented IQ <85 and those with severe psychiatric or neurodevelopmental disorder (e.g., psychosis, intellectual disability, autism spectrum disorder) were excluded from the study due to concerns regarding reliability of their self-report of depressive symptoms. Inclusion criteria for caregivers included English fluency. Inclusion/exclusion criteria were confirmed with the electronic medical records and healthcare providers.
Measures
Youth completed the CDI-2, a 28-item measure of depressive symptoms, divided into four different subscales, that is, interpersonal problems (IP), negative mood (NM), ineffectiveness (IF), and negative self-esteem (NS). The four subscales are aggregated and yield a Total score. The CDI-2 consists of 28 item sets, each of which contains three statements that mirror the severity of the target symptom from 0 (none) to 2 (definite), and youth are asked to choose the statement that best fits them. Youth are prompted to answer based on their behavior during the past 2 weeks. Total T-scores ≥65 indicate clinical depressive symptoms, and T-scores ≥65 on the subscales indicate clinical symptoms in those specific domains. 13, 15 The CDI/CDI-2 has been used extensively in YWE, and has shown excellent psychometric properties including internal consistency, test-retest reliability, and construct validity. from the adult NDDI-E. 9 The NDDI-E-Y has shown strong psychometrics, including internal consistency, construct validity, and sensitivity/specificity in several validation studies. 10, 12 On the NDDI-E-Y, youth are asked to "mark the answer that best describes how often you have the following feelings and thoughts within the past 2 weeks," and response choices include 0 (never) to 3 (always). Aggregated raw scores create a Total score with higher values indicating worse depressive symptoms; specifically, scores of 32 and above indicate significant depressive symptomatology. 12 In addition, youth completed the 8-item Depression Scale Short Form of the Pediatric Neuro-QOL (Neuro-QOL SF), which was designed to assess HRoL in children with neurologic conditions, including epilepsy. 11, 13 In the domain of "emotional health," the Short Form Depression Scale includes 8 symptoms of pediatric depression. 19 For each item, there are 5 response choices ranging from 1 "never" to 5 "almost always." Higher scores indicate worse symptoms. Responses on the Neuro-QOL SF are totaled to comprise a total raw score. Raw scores are then converted to T-scores. The Neuro-QOL technical manual states that one standard deviation above the mean (T = 60) indicates significant symptomatology. 20 Caregivers completed the 9-item Seizure Severity Scale (SSS) to provide a caregiver report of seizure severity. 21, 22 On the SSS, type and symptoms of seizures are rated as 0 (never), 1 (sometimes), 2 (usually), and 3 (always). Other items measuring time and length of seizures are coded as 0 (<1 min), 1 (between 1 and 2 min), 2 (between 2 and 5 min), and 3 (>5 min). Postictal confusion duration is coded as 0 (<1 min), 1 (between 1 and 5 min), 2 (between 5 min and 1 h), and 3 (>1 h) Higher scores on the SSS indicate that seizures are more disruptive. The SSS has demonstrated strong psychometrics in previous studies. 10, 23 Demographic (e.g., race and gender) and epilepsy (e.g., epilepsy classification [idiopathic, symptomatic, and cryptogenic], seizure type [generalized convulsive, generalized nonconvulsive, partial, and unspecified] age at onset, time since diagnosis, and current medications) variables were abstracted by a practitioner with >25 years of experience in epilepsy (GS) from the electronic medical record in accordance with the National Institute of Neurological Disorders and Stroke guidelines for common data elements. 24 Seizure frequency was rated using the following Likert scale (multiple per day, 1 per day, >1 per week, 1 per week, 1-3 per month, <11 per year, none).
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Procedure
Youth and caregivers completed the above-mentioned self-report measures during a routine epilepsy clinic visit. Demographic and medical data were abstracted from the electronic medical record. The time frame for the study was August 2013 to December 2014.
Standard protocol approvals, registrations, and patient consents
The site's institutional review board approved the study protocol. During a routine epilepsy visit at a comprehensive epilepsy center, eligible youth and caregivers were approached, and informed consent from the caregiver and assent from the youth were obtained in accordance with the established methods of the institutional review board. As part of the consent process, families were informed that they would receive modest compensation for their time.
Statistical analysis
Data analyses were conducted using the SAS software package 9.4. 25 A linear regression modeling approach was used to investigate the following: (1) whether the NDDI-E-Y predicts overall depressive symptoms (CDI-2 Total score) or specific depressive symptom clusters (e.g., CDI-2 subscales) as single predictor in the model and when adjusted for covariates and (2) whether the NDDI-E-Y or Neuro-QOL SF is a better predictor of CDI-2 Total and subscale scores in youth with epilepsy. We investigated the relationship of NDDI-E-Y with CDI-2 in a bivariate model as well as adjusted for potentially influential variables such as age, gender, race/ethnicity, age at seizure onset, number of AEDs, seizure classification, time since diagnosis, seizure severity, and seizure frequency. These covariates were selected based on previous findings in the pediatric epilepsy and depression literature (i.e., demonstrated gender and developmental differences in depression, 1, 26 and relationships among seizure variables and behavioral health outcomes 3 ). In addition to adjusted R 2 , that is, the proportion of total variance in the dependent variable explained by covariates included in the model, the root mean squared error (RMSE) was used, which can be interpreted as the standard deviation of the unexplained variance in a given model. RMSE was assessed to compare goodness of fit between models for the CDI-2 Total score and (individually) for each CDI-2 subscale. Independent t-tests were used to compare the standardized beta coefficients between the models for Total and subscales T-score with NDDI-E-Y as a single predictor and when NDDI-E-Y was adjusted for additional covariates. Subsequently, CDI-2 Total and subscale Tscores were dichotomized into scores of ≥65 versus scores <65, and NDDI-E-Y Total scores were dichotomized into scores of ≥32 versus <32.
11 Concordance and discordance between NDDI-E-Y and CDI-2 were assessed to determine frequencies and proportions of YWE categorized as having versus not having depressive symptoms for both instruments and were reported along with Kendall's tau.
For aim 2, bivariate linear regression models were used to assess NDDI-E-Y and Neuro-QOL SF as predictors of CDI-2 Total and subscale scores; slopes, that is, regression coefficients of the models, were compared using independent ttests. To assess whether explained variance in CDI-2 scores increased, NDDI-E-Y and Neuro-QOL SF were entered together in subsequent models; R-squared change in the nested models was assessed using F-tests, that is, the model including NDDI-E-Y alone was compared to the model including NDDI-E-Y and Neuro-QOL SF. Furthermore, bivariate logistic regression was used to determine the area under the receiver-operating characteristic (ROC) curve (AUC) with NDDI-E-Y and Neuro-QOL SF individually as independent variables, respectively. AUCs under the two independent ROC curves were compared using chi-square tests. Sensitivity and specificity point estimates as well as several measures of test accuracy including Youden Index, Mathews Correlation Coefficient, and total accuracy were obtained for the dichotomized CDI-2 score and Neuro-QOL SF score (using a cutoff score of 60). (AUC was previously determined for NDDI-E-Y in the prediction of CDI-2 Total scores.) 12 
Results
Sixty-eight percent of the 99 participants were female; 31.7% identified as a racial/ethnic minority, and 87.1% were diagnosed with idiopathic epilepsy. The most frequent seizure type was partial seizure (40.8%). Furthermore, the current sample comprised youth with chronic epilepsy (M years = 6.6) with all but one taking at least one AED (one AED = 43.43%, two AEDs = 36.36%, and three AEDs = 19.19%) and over half with medically refractory epilepsy.
A more detailed description of participants' seizure and demographic information can be found in Table 1 . Twenty percent of the participants had scores ≥65 on the CDI-2, 10.1% had scores >60 on the Neuro-QOL SF, and 23.2% had scores of ≥32 on the NDDI-E-Y.
For aim 1, we first investigated bivariate regression models with CDI-2 Total T-scores as dependent variables and NDDI-E-Y as the independent variable (Table 2 model 1). Variance explained in CDI-2 T-scores ranged from 48% for Total score to 28% for CDI-2 NM subscale. Second, we examined the relationship between NDDI-E-Y and CDI-2 Total scores when adjusting for seizure and demographic variables ( Table 2 model 2). In models including only the NDDI-E-Y and one of these adjustment variables (not shown), only age was statistically significantly associated with the IP subscale (p = 0.031) and seizure severity with the IF subscale (p = 0.023). In the full models that included all adjustment variables combined, the relationship for age and IP did not hold (p = 0.06); however, age was significantly associated with CDI-2 total (p = 0.05) and NM subscale (p = 0.05). Seizure severity remained significantly associated with the IF subscale (p = 0.02). There was a statistically significant association of NDDI-E-Y total raw scores with all CDI-2 T-scores (p < 0.001). In these adjusted models, variance explained in CDI-2 T-scores ranged from 45% for Total and IF scores to 27% for NM. Change in model fit through inclusion of covariates decreased slightly for all NDDI-E-Y models. For example, for CDI-2 Total score including the seven covariates, age, gender, race/ethnicity, seizure severity, seizure frequency, epilepsy classification, and time since diagnosis, reduced model fit by 4%, that is, RMSE, increased by 4% (Table 2 ).
In addition, standardized beta coefficients (slopes) from bivariate and multivariable models were compared between CDI-2 Total score and subscales. When NDDI-E-Y was adjusted for the set of predictors, the model had a statistically significantly higher R-squared value, that is, it explained more variance in the IF subscale compared to the NM subscale (p = 0.046); no other differences were observed, indicating that with one exception NDDI-E-Y predicted Total scores and subscales similarly (Tables 3a  and b ). When dichotomized NDDI-E-Y and CDI-2 Total scores were compared, there was agreement on 85.9% (85/ 99) of participants. Both instruments agreed on classifying 70 YWE as not having significant depressive symptoms and 15 as having depressive symptoms. In contrast, the NDDI-E-Y classified an additional six youths as expressing symptoms of depression not considered in the clinical range by the CDI-2, whereas the CDI-2 classified four additional youth as having depressive symptoms not classified as such by the NDDI-E-Y (Kendall's tau = 0.69, 95% CI 0.50-0.87). For aim 2, we used linear regression with CDI-2 Total T-score and subscale T-scores as dependent variables, and NDDI-E-Y total raw score or Neuro-QOL SF T-score, individually and combined as predictor variables. Variance explained in CDI-2 T-scores ranged from 48% to 29% for NDDI-E-Y and from 37% to 15% for the Neuro-QOL SF (Table 4 ). The NDDI-E-Y explained a statistically significantly higher proportion of the variance in the CDI-2 IF subscale compared to the Neuro-QOL SF (p = 0.05) ( Table 4) . No other statistically significant differences were found.
When combining the NDDI-E-Y and the Neuro-QOL SF as predictor variables in the model, we observed a statistically significant increase in R-squared for the CDI-2 IP subscale (40%; NDDI-E-Y, 36% and Neuro-QOL SF, 35%); no further differences were observed. When adjusting p-values for multiple comparisons, no statistically significant differences remain.
When including the covariates and the Neuro-QOL SF along with the NDDI-E-Y in the models, there were no significant relationships between the covariates and the CDI-2 Total or subscale scores. Change in model fit through inclusion of covariates slightly decreased for all Neuro-QOL SF models. For example, fit for the CDI-2 Total model was reduced by 3% (i.e., RSME increased by 3%; Table S1 ).
Bivariate logistic regression showed that for a one unit increase in NDDI-E-Y score, the odds of having a CDI-2 Total score above the suggested clinical threshold (T ≥65) increased by 1.28. For a one unit increase in NDDI-E-Y score, the odds of having a CDI-2 subscale T-score >65 ranged from 1.19-1.33. Using a cutoff of 32 on the NDDI-E-Y, AUC for prediction of CDI-2 subscales ranged from 0.808-0.905. Specificity was consistently high, with all values above 87%, whereas sensitivity ranged from 61.1% to 84.6% (Table 5 ). For a one unit increase in Neuro-QOL SF score, the odds of having a CDI-2 T-score >65 for Total was 1.25, and for subscales ranged from 1.10-1.31. The Neuro-QOL SF differentiated between participants having higher versus lower CDI-2 Total scores (AUC = 0.857) and CDI-2 subscales (AUC ranged from 0.727-0.894). Sensitivity was 42.1%, positive predictive value was 80%, negative predictive value was 87%, and specificity was 97.4% for the Neuro-QOL SF in predicting CDI-2 Total scores >65. Furthermore, the Neuro-QOL SF explained 34% of variance in the CDI-2. When comparing predictive performance of NDDI-E-Y and Neuro-QOL SF for the dichotomized CDI-2 using AUC, no statistically significant differences were observed (Table 5) ; however, AUC values were consistently higher for the NDDI-E-Y across CDI-2 Total and subscales. 
Discussion
The aims of this study were twofold: to investigate whether (1) the NDDI-E-Y predicts overall depressive symptoms (CDI-2 Total score) or specific depressive symptom clusters (e.g., CDI-2 subscales) as single predictor in the model and when adjusted for covariates and (2) the NDDI-E-Y or Neuro-QOL SF is a better predictor of CDI-2 Total and subscale scores in youth with epilepsy. a Area under the curve (AUC) for the CDI-2 total predicted by the NDDI-E-Y has been previously published (Wagner et al. 11 ). b All p-values associated with odds ratios < 0.001. Findings for aim 1 revealed that, in general, the NDDI-E-Y predicted more variance in overall depressive symptoms (45%) and feelings of ineffectiveness (IF 45%) compared to other specific clusters of depressive symptoms (negative mood [NM 27%], interpersonal problems [IP 34%], negative self-esteem [NS 39%]) on the CDI-2; however, differences were not statistically significant. In other words, the NDDI-E-Y predicted CDI-2 Total and subscale scores similarly. There was one exception: the NDDI-E-Y was a stronger predictor of feelings of ineffectiveness compared to negative mood. The NDDI-E-Y also showed weaker sensitivity for CDI-2 NM, suggesting that the NDDI-E-Y may not focus on negative mood in YWE. Indeed, item selection for the NDDI-E, and subsequently the NDDI-E-Y, excluded items associated with AED side effects, which largely include mood symptoms. 27, 28 In contrast, the NDDI-E-Y explained 45% of variance in thoughts and feelings of ineffectiveness (e.g., "Nothing is fun at all," "My schoolwork is not as good as before," or "I can never be as good as other kids") and 38% of negative self-esteem. Indeed, children with epilepsy often have lower self-esteem and self-confidence, perhaps due to neurocognitive and social challenges associated with epilepsy. 29 Recent research has also provided support for two clusters of depressive symptoms in persons with epilepsy, with the more common cluster consisting of a cognitive phenotype (e.g., self-critical cognitions). 30 It appears that the NDDI-E-Y explains more variance in these self-critical cognitions than anhedonia or mood behaviors associated with DSM-5 depression. Current results, in combination with previous findings, suggest that the NDDI-E-Y is strong predictor of overall depressive symptoms and feelings of ineffectiveness on the CDI-2 and has strong sensitivity and specificity in determining high versus low CDI-2 depressive symptoms. 12 Inclusion of the covariates did not increase variance explained by the model. When simultaneously including the demographic and seizure covariates and the NDDI-E-Y in the regression models, only age was a significant predictor of CDI-2 Total scores. Demographic and seizure variables were included as covariates for theoretical purposes and based on previous research. Similar to previous studies, the older the patients, the higher the depressive symptom scores.
1 Seizure severity is complicated; in the current results, it emerged as a significant single predictor but lost significance when multiple covariates were included. Previous studies have revealed unequivocal findings. 31 Results for aim 2 demonstrated that the Neuro-QOL SF was also a significant predictor of overall CDI-2 depressive symptoms and subscale symptom clusters and accounted for the lowest amount of variance (15.7%) in CDI-2 NM. Notably, the AUC and percent of variance explained were higher for the NDDI-E-Y compared to the Neuro-QOL SF across all CDI-2 scores; however, neither the p-value for the comparison of AUC nor the comparison of the regression slopes showed significant differences. In other words, neither the NDDI-E-Y nor the Neuro-QOL SF emerged as a superior predictor of CDI-2 depressive symptoms. However, several important findings provide support for clinical use of the NDDI-E-Y over the Neuro-QOL SF as a depression screening tool in YWE.
The NDDI-E-Y Total score explained a statistically significantly higher proportion of the variance in the CDI-2 IF subscale compared to the Neuro-QOL SF. As was mentioned previously, the NDDI-E-Y was created with an emphasis on depressive symptoms that do not have significant overlap with AED side effects, and therefore, the content of the NDDI-E-Y appears to include more cognitivebased depressive symptoms 27, 28 than the Neuro-QOL SF. This finding is important given the recent evidence for a more common cognitive phenotype of depression in persons with epilepsy. 30 The NDDI-E-Y also had much higher sensitivity, or true positive rate, than the Neuro-QOL SF in predicting high versus low depressive symptoms on the CDI-2 Total score (79% vs. 42%) and across subscale scores. In other words, the NDDI-E-Y was accurate at identifying those YWE who had scores indicating clinical levels of depressive symptoms on the CDI-2 (≥65); however, the Neuro-QOL SF identified only 42% of youth scoring above the clinical threshold for depressive symptoms on the CDI-2. In contrast, the Neuro-QOL SF specificity (true negative rate) indices were slightly, but not significantly, higher than the NDDI-E-Y across CDI-2 scores. However, in the case of depressive symptoms, sensitivity should be viewed as the most relevant indicator to reduce the chance of false-negative cases and therefore is more critical than specificity performance for a screening measure given the potential risk to not identify a YWE with comorbid depressive symptoms (e.g., suicidal ideation and poor quality of life).
There are additional concerns for the Neuro-QOL SF regarding its development and validation. Indeed, it was developed specifically for children with neurologic disorders, including epilepsy; however, the original validation study for the Depression Scale of the Neuro-QOL SF included no YWE. 13 The more recent study comprised a small sample of 61 youth with well-controlled epilepsy who were primarily prescribed one AED.
14 Therefore, it is difficult to generalize these results to youth with treatment-resistant epilepsy, who are more likely to present with depressive symptoms. 32 Furthermore, despite the findings reported in these papers, there is concern regarding the theoretical underpinnings and content validity of the Depression Short Form. The Neuro-QOL SF is purported to be a measure of "health-related quality of life," and yet the Depression Short Form consists of "symptoms of pediatric depression." 33 Depressive symptoms are associated with poorer HRQoL in YWE 2, 34 ; however, depressive symptoms and quality of life are not synonymous constructs as conceptualized by the Neuro-QOL SF developers. 13 Instead, they are related constructs, with strong evidence for depression as a predictor of HRQoL. 2 Finally, the Neuro-QOL SF does not contain a question regarding suicidal ideation.
Twenty percent of our sample endorsed "rarely" or "sometimes" thinking about dying or killing themselves in the past 2 weeks, 11 and other studies have shown similar rates of suicidal ideation. 2 Inclusion of a suicidal ideation question is very relevant to the screening of depressive symptoms in YWE. Providers often avoid depression screening measures that contain questions assessing suicidal ideation due to fear of how to intervene or perceived lack of resources. 35 It is not appropriate to ignore these very concerning symptoms, and with appropriate protocols developed for handling serious or imminent concerns (e.g., positive response on this item requires further suicidal evaluation to potentially include a safety plan, referral for immediate mental health services, and so on) and resources identified, providers can be educated about how to address such symptoms.
The NDDI-E-Y was developed specifically to be a screener for depressive symptoms in youth with epilepsy. Current and previous results support its strong internal consistency, specificity/sensitivity, and construct validity, 10, 11 and the use of the NDDI-E-Y over the Neuro-QOL SF for depressive symptom screening in YWE, particularly in YWE who have chronic epilepsy and are prescribed more than one AED. In this current study of a sample of youth with chronic treatment-resistant epilepsy (56% have had a seizure in the past year, 57% on polytherapy), 20% of youth reported elevated depressive symptoms on the CDI-2 and 23% on the NDDI-E-Y, a rate similar to that of a recent study (23%), 2 which again underscores the importance of depression screening during routine epilepsy care.
The primary limitations of this study include a sample representative of female and white non-Hispanic patients. Furthermore, although demographic information was obtained via electronic medical record review, we unfortunately did not have access to information about socioeconomic status. Future studies should explore the potential relationship between socioeconomic status and the NDDI-E-Y. In addition, the study involved solely self-report measures and did not include a diagnostic interview to determine a diagnosis of depression. A recent paper highlighted the importance of selecting diagnostic tools used to assess behavioral health symptoms/disorders in YWE. 36 Although the NDDI-E-Y is not a diagnostic tool, it does provide a measure of current symptom burden/severity, and the NDDI-E-Y was evaluated against the CDI-2, a widely used measure of depressive symptoms. In addition,, we did not employ counterbalancing of self-report measure administration. The depressive screening tools were given in the following order to all participants: Neuro-QOL SF, CDI-2, and NDDI-E-Y. However, no participant reported fatigue or asked for additional time to complete measures; therefore, fatigue did not appear to have played a role in completion of these measures. Finally, use of binary variables (above/below cutoff score) of the survey's results in loss of information compared to use of scores as continuous variables; however, this reflects the typical use of the scales in clinical practice.
In conclusion, depressive symptoms in YWE are recognized as a major concern 5,37,38 but are often underdiagnosed. 16, 39, 40 The NDDI-E-Y provides a brief, reliable and valid tool that is free (with permission of the authors). It can be feasibly integrated in routine epilepsy care without the presence of a mental/behavioral health professional. Scores of ≥32 on the NDDI-E-Y can be used to identify YWE with clinical depressive symptoms. 11 If procedures are put into place for who will administer (i.e., patienthanded NDDI-E-Y to complete in the waiting room), score (algorithm included in electronic medical record) ,and interpret (i.e., nurse to review while taking patient history, advanced nurse practitioner, or physician to review with patient during visit), use of the NDDI-E-Y in routine epilepsy care will take 5 min of the patient's otherwise down time and 5 min for healthcare providers to review. Obviously, discussion of sensitive and imminent concerns may take longer and require further evaluation. Procedures will be necessary for the appropriate handling of suicidal ideation endorsement expedient referrals for further evaluation and/or treatment. Such resources will vary depending on each site's availability of behavioral health professionals and expected roles of the epilepsy healthcare providers. Notably, screening is not only important at epilepsy diagnosis but should continue over the disease course, as depressive symptoms in YWE are not stable over time. 2 Continual screening across the course of epilepsy treatment is necessary and may be readily accessible through tools such as the NDDI-E-Y. Future research should focus on the ability of the NDDI-E-Y to identify those youth who meet DSM-5 criteria for depression, and determination of clinically meaningful change estimates. 41 Validation with other minority groups (e.g., Hispanic) is also necessary. Finally, age was related to CDI-2 scores in several of the current study's models, which continue to highlight the complexity of the relationships among sociodemographic and seizure variables and the need for future investigation.
